ADMA Biologics Faces Class Action for Investor Misleading
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Source: Globenewswire
- Class Action Initiated: Robbins LLP has announced a class action against ADMA Biologics on behalf of all investors who purchased its securities between August 9, 2024, and March 25, 2026, highlighting significant investor concerns regarding the company's transparency.
- False Statement Allegations: The complaint alleges that ADMA Biologics failed to disclose related party transactions, engaged in channel stuffing to create an illusion of revenue, and lacked adequate internal controls, severely undermining investor confidence in the company's operations.
- Stock Price Plummet: Following the March 24, 2026 report from Culper Research revealing that ADMA's revenue growth was artificially inflated through channel stuffing, the stock price fell by $2.26, or 16.6%, further eroding investor trust.
- Legal Implications: Investors may participate in the class action as lead plaintiffs to represent other shareholders, indicating a pressing need for improved corporate governance to protect investor rights and pursue potential compensation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Class Action for Investor Misleading
- Class Action Initiated: Robbins LLP has announced a class action against ADMA Biologics on behalf of all investors who purchased its securities between August 9, 2024, and March 25, 2026, highlighting significant investor concerns regarding the company's transparency.
- False Statement Allegations: The complaint alleges that ADMA Biologics failed to disclose related party transactions, engaged in channel stuffing to create an illusion of revenue, and lacked adequate internal controls, severely undermining investor confidence in the company's operations.
- Stock Price Plummet: Following the March 24, 2026 report from Culper Research revealing that ADMA's revenue growth was artificially inflated through channel stuffing, the stock price fell by $2.26, or 16.6%, further eroding investor trust.
- Legal Implications: Investors may participate in the class action as lead plaintiffs to represent other shareholders, indicating a pressing need for improved corporate governance to protect investor rights and pursue potential compensation.
See More
Reminder of ADMA Biologics Securities Fraud Lawsuit
- Lawsuit Deadline: Investors must file a lead plaintiff motion by August 10, 2026, to protect their rights in the class action concerning ADMA Biologics securities purchased between August 9, 2024, and March 25, 2026.
- Stock Price Plunge: Following a report from Culper Research alleging channel stuffing and undisclosed related party transactions, ADMA's stock price fell by $3.96, or 29.1%, over two days, closing at $9.63 per share, significantly harming investors.
- False Statements Allegation: The complaint alleges that ADMA made materially false and misleading statements throughout the class period, failing to disclose adverse facts about its business operations and prospects, which misled investors.
- Legal Consultation Access: Investors seeking more information or wishing to participate in the lawsuit can contact the Law Offices of Howard G. Smith via email or phone to ensure their legal rights are protected.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ADMA Biologics, alleging violations of federal securities laws during the period from August 9, 2024, to March 25, 2026, impacting all investors who purchased ADMA securities during this timeframe.
- Allegations of Misrepresentation: The complaint claims that the defendants made false and/or misleading statements and failed to disclose critical information throughout the class period, potentially leading to investor losses and raising concerns about the company's transparency in the market.
- Investor Participation Opportunity: Affected investors have until August 10, 2026, to request to be appointed as lead plaintiff, with the option to participate in any recovery without needing to serve in this role, highlighting the flexibility of the legal process for investors.
- No-Cost Legal Services: The law firm operates on a contingency fee basis, meaning they will only charge for out-of-pocket expenses and attorney fees if they successfully recover funds, thereby reducing the financial burden on investors and encouraging their participation in the lawsuit.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily due to allegations that its reported 20% growth for 2025 was driven by a channel stuffing scheme, resulting in significant stock price drops and substantial investor losses.
- Stock Price Collapse: On March 24, 2026, ADMA's stock plummeted from $13.59 to $11.33, a 16.6% drop, followed by a further 15% decline the next day, reflecting severe market skepticism regarding its financial transparency.
- Legal Proceedings: The class action is pending in the U.S. District Court for New Jersey, with investors required to apply by August 10, 2026, to lead the case, indicating a loss of trust in the company's management.
- Market Reaction: A report by Culper Research exposed ADMA's alleged financial misconduct, leading to a downgrade by Cantor, which exacerbated investor panic and negatively impacted the company's market reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file a motion with the court by August 10, 2026, to establish their representative status in the class action, ensuring their active participation in the litigation process.
- Potential Compensation Mechanism: Investors joining the class action may be entitled to compensation without any upfront costs through a contingency fee arrangement, providing financial security and legal support for affected investors.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP has announced a class action lawsuit against ADMA Biologics on behalf of all investors who purchased its securities between August 9, 2024, and March 25, 2026, highlighting significant investor concerns regarding the company's transparency.
- Allegations of False Statements: The complaint alleges that ADMA Biologics made false and misleading statements during this period, failing to disclose related party transactions and inadequate internal controls, which severely undermined investor confidence in the company's operations.
- Stock Price Volatility: Following the March 24, 2026, report from Culper Research revealing that ADMA's revenue growth was achieved through channel stuffing, the stock price plummeted by $2.26, a 16.6% drop, further eroding market trust in the company.
- Legal Implications and Investor Rights: Investors may participate in the lawsuit to seek compensation, with Robbins LLP offering contingency-based representation, emphasizing the importance of corporate governance and investor rights protection.
See More
ADMA Biologics Faces Class Action for Investor Misleading
- Class Action Initiated: Robbins LLP has announced a class action against ADMA Biologics on behalf of all investors who purchased its securities between August 9, 2024, and March 25, 2026, highlighting significant investor concerns regarding the company's transparency.
- False Statement Allegations: The complaint alleges that ADMA Biologics failed to disclose related party transactions, engaged in channel stuffing to create an illusion of revenue, and lacked adequate internal controls, severely undermining investor confidence in the company's operations.
- Stock Price Plummet: Following the March 24, 2026 report from Culper Research revealing that ADMA's revenue growth was artificially inflated through channel stuffing, the stock price fell by $2.26, or 16.6%, further eroding investor trust.
- Legal Implications: Investors may participate in the class action as lead plaintiffs to represent other shareholders, indicating a pressing need for improved corporate governance to protect investor rights and pursue potential compensation.
See More
Reminder of ADMA Biologics Securities Fraud Lawsuit
- Lawsuit Deadline: Investors must file a lead plaintiff motion by August 10, 2026, to protect their rights in the class action concerning ADMA Biologics securities purchased between August 9, 2024, and March 25, 2026.
- Stock Price Plunge: Following a report from Culper Research alleging channel stuffing and undisclosed related party transactions, ADMA's stock price fell by $3.96, or 29.1%, over two days, closing at $9.63 per share, significantly harming investors.
- False Statements Allegation: The complaint alleges that ADMA made materially false and misleading statements throughout the class period, failing to disclose adverse facts about its business operations and prospects, which misled investors.
- Legal Consultation Access: Investors seeking more information or wishing to participate in the lawsuit can contact the Law Offices of Howard G. Smith via email or phone to ensure their legal rights are protected.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against ADMA Biologics, alleging violations of federal securities laws during the period from August 9, 2024, to March 25, 2026, impacting all investors who purchased ADMA securities during this timeframe.
- Allegations of Misrepresentation: The complaint claims that the defendants made false and/or misleading statements and failed to disclose critical information throughout the class period, potentially leading to investor losses and raising concerns about the company's transparency in the market.
- Investor Participation Opportunity: Affected investors have until August 10, 2026, to request to be appointed as lead plaintiff, with the option to participate in any recovery without needing to serve in this role, highlighting the flexibility of the legal process for investors.
- No-Cost Legal Services: The law firm operates on a contingency fee basis, meaning they will only charge for out-of-pocket expenses and attorney fees if they successfully recover funds, thereby reducing the financial burden on investors and encouraging their participation in the lawsuit.
See More
ADMA Biologics Faces Class Action Lawsuit for Securities Fraud
- Lawsuit Background: ADMA Biologics is facing a class action lawsuit for securities fraud, primarily due to allegations that its reported 20% growth for 2025 was driven by a channel stuffing scheme, resulting in significant stock price drops and substantial investor losses.
- Stock Price Collapse: On March 24, 2026, ADMA's stock plummeted from $13.59 to $11.33, a 16.6% drop, followed by a further 15% decline the next day, reflecting severe market skepticism regarding its financial transparency.
- Legal Proceedings: The class action is pending in the U.S. District Court for New Jersey, with investors required to apply by August 10, 2026, to lead the case, indicating a loss of trust in the company's management.
- Market Reaction: A report by Culper Research exposed ADMA's alleged financial misconduct, leading to a downgrade by Cantor, which exacerbated investor panic and negatively impacted the company's market reputation.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file a motion with the court by August 10, 2026, to establish their representative status in the class action, ensuring their active participation in the litigation process.
- Potential Compensation Mechanism: Investors joining the class action may be entitled to compensation without any upfront costs through a contingency fee arrangement, providing financial security and legal support for affected investors.
- Law Firm Background: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
ADMA Biologics Faces Class Action Lawsuit
- Class Action Initiated: Robbins LLP has announced a class action lawsuit against ADMA Biologics on behalf of all investors who purchased its securities between August 9, 2024, and March 25, 2026, highlighting significant investor concerns regarding the company's transparency.
- Allegations of False Statements: The complaint alleges that ADMA Biologics made false and misleading statements during this period, failing to disclose related party transactions and inadequate internal controls, which severely undermined investor confidence in the company's operations.
- Stock Price Volatility: Following the March 24, 2026, report from Culper Research revealing that ADMA's revenue growth was achieved through channel stuffing, the stock price plummeted by $2.26, a 16.6% drop, further eroding market trust in the company.
- Legal Implications and Investor Rights: Investors may participate in the lawsuit to seek compensation, with Robbins LLP offering contingency-based representation, emphasizing the importance of corporate governance and investor rights protection.
See More
